SynCardia Completes First In Vivo Implantations of Next-Generation Emperor Total Artificial Heart




SynCardia Completes First In Vivo Implantations of Next-Generation Emperor Total Artificial Heart

Significant milestone reached in advancing a driverless total artificial heart, strengthening Picard Medicals leadership in total artificial heart technology

TUCSON, Ariz., Nov. 19, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it has successfully completed the first in vivo implantations of the fully implantable Emperor Total Artificial Heart (TAH). The positive outcomes observed following the implantations mark a major milestone in the development of the Emperor platform as the next-generation successor to the clinically proven, FDA-approved SynCardia Total Artificial Heart (“STAH”).

Patrick NJ Schnegelsberg, CEO of Picard Medical, stated, “We are excited by these initial data. The successful completion of these first implantations brings SynCardia back to the forefront of innovation in total artificial heart technology. This milestone strengthens our position as the global leader in total artificial hearts and is yet another step that validates the potential of the Emperor platform.”

The Emperor TAH was successfully implanted in three pre-clinical models, and each model was taken off bypass without any issues. Throughout the observation periods, the device provided full and stable blood circulation, used energy efficiently, and operated without technical problems. The Emperor TAH performed in a way that closely mirrors how a natural human heart works. It produced stable hemodynamics (steady, controlled blood flow), showed physiologic preload sensitivity (the pump output increased naturally as more blood entered the device), and maintained afterload independence (consistent pumping performance even as systemic vascular resistance changed). These behaviors reflect the Frank Starling response, the natural mechanism by which the heart adjusts its pumping strength based on how much blood fills it. All results were consistent with Picard Medicals laboratory performance goals for the Emperor platform.

“Our very positive experience with implanting the next-generation TAH in three separate in vivo models confirms that the Emperor platform is progressing as designed and confirms its potential to become a fully implantable alternative to heart transplantation,” added Andre R. Simon, MD, PhD, FRCS, Vice President of Medical Affairs. “The performance characteristics observed in each of these acute experiments validate key engineering choices and support continued program acceleration for this novel device which could be an even further improvement to a patient’s quality of life.”

SynCardia will continue with additional pre-clinical studies to refine the final system parameters. The Emperor platform is designed to expand the total artificial heart market by delivering a fully implantable system with improved performance, energy efficiency, and patient usability.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference




OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37^th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3^rd at 12:00 p.m. Eastern time.

Investors interested in scheduling a meeting with OPKO management should contact their Piper Sandler representative.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

Alliance Advisors IR
Yvonne Briggs, 310-691-7100
ybriggs@allianceadvisors.com
or
Bruce Voss, 310-691-7100
bvoss@allianceadvisors.com

Meihua International Announces 1-For-100 Reverse Share Split




Meihua International Announces 1-For-100 Reverse Share Split

YANGZHOU, Nov. 19, 2025 (GLOBE NEWSWIRE) — Meihua International Medical Technologies Co., Ltd. (“Meihua” or the “Company”) (Nasdaq: MHUA),  reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced that it would effectuate a reverse share split of its outstanding ordinary shares, par value of $0.0005 per share, at a ratio of 1-for-100, and implement its dual-class share structure, to be effective at the open of business on Monday, November 24, 2025.

Following the reverse share split, the Company’s class A ordinary shares will have a new par value of $0.05 per share and will continue to trade on Nasdaq under the symbol “MHUA” with the new CUSIP number, G5966G116, at the opening of The Nasdaq Capital Market (“Nasdaq”) on Monday, November 24, 2025 The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per Ordinary Share for continued listing on Nasdaq.

No fractional shares will be issued in connection with the reverse share split and all such fractional interests will be rounded up to the nearest whole number of Class A Ordinary Shares. In addition, the reverse share split will apply to the Class A Ordinary Shares issuable upon the exercise of the Company’s outstanding derivative securities, with proportionate adjustments to be made to the exercise prices and number of derivates thereof and under the Company’s equity incentive plans.

The reverse share split will reduce the number of issued and outstanding shares of the Company’s Class A Ordinary Shares from approximately 56 million to approximately 0.56 million.

On November 8, 2025, the shareholders of the Company approved the proposed reverse share split and the dual-class share structure.

VStock Transfer, LLC is acting as the exchange agent and paying agent for the reverse share split. Shareholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse share split.

VStock Transfer, LLC will provide instructions to any shareholders with certificates regarding the process in connection with the exchange of pre-reverse share split share certificates for ownership in book-entry form or share certificates on a post-reverse share split basis. Shareholders are encouraged to contact their bank, broker or custodian with any procedural questions.

About Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies Co., Ltd. is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under the Company’s own brands and are also sourced and distributed from other manufacturers. The Company has received an international “CE” certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.

For more information, please visit www.meihuamed.com.

Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua. 

Forward-Looking Statements

The statements in this press release regarding the Company’s future expectations, plans and prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, goals, objectives, strategies, future events, expected performance, assumptions and any other statements of fact that have not occurred. Any statements that contain the words “may”, “will”, “want”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “calculate” or similar statements that are not factual in nature are to be considered forward-looking statements. Actual results may differ materially from historical results or from those expressed in these forward-looking statements as a result of a variety of factors. These factors include, but are not limited to, the Company’s strategic objectives, the Company’s future plans, market demand and user acceptance of the Company’s products or services, technological advances, economic trends, the growth of the trucking services market in China, the Company’s reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, fluctuations in China’s macroeconomic conditions, and the risks and assumptions disclosed in the Company’s reports provided to the CSRC (China Security Regulatory Commission). The potential acquisition involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements including but not limited to statements about the potential benefits of the potential acquisition; the anticipated timing of closing of the potential acquisition (including failure to obtain necessary regulatory approvals) and the possibility that the potential acquisition does not close; risks related to the ability to realize the anticipated benefits of the potential acquisition, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the potential acquisition making it more difficult to maintain business and operational relationships; negative effects of announcing the potential acquisition or the consummation of the potential acquisition on the market price of our common stock or operating results; costs associated with the potential acquisition; unknown liabilities; and the risk of litigation and/or regulatory actions related to the potential acquisition. For these and other related reasons, we advise investors not to place any reliance on these forward-looking statements, and we urge investors to review the Company’s relevant SEC filings for additional factors that may affect the Company’s future results of operations. The Company undertakes no obligation to publicly revise these forward-looking statements subsequent to the filing of these documents as a result of changes in particular events or circumstances.

For further information, please contact.

IR Department
Email: secretary@meihuamed.com
Tel: +86-0514-89800199

ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2025




ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2025

TEL AVIV, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including updated interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment of patients with low-grade UTUC, will be presented at the 26^th Annual Meeting of the Society of Urologic Oncology (SUO 2025) taking place December 2 – 5, 2025, in Phoenix, Arizona.

Poster & Session Details:

Poster Title: ENLIGHTED Phase 3 study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC)
Presenter: Vitaly Margulis, M.D., Professor of Urologic Oncology, University of Texas Southwestern
Medical Center
Poster Number: 166
Session Title: SUO Top Abstract Tour
Session Date & Time: December 4, 2025, 4:30 PM MST

In addition, the Company recently delivered an encore presentation of data from the Phase 3 ENLIGHTED trial at the 17^th European Multidisciplinary Congress on Urological Cancers (EMUC 2025) on November 15, 2025. The poster, titled “ENLIGHTED phase 3 study: Interim Results of Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic therapy (VTP) in the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC),” featured an interim analysis that had previously been presented at ASCO 2025, showing Padeliporfin VTP induced a complete response (CR) in 73% (27/37) of evaluable patients and maintained a safe and well-tolerated profile. The interim analysis captured results from 50% of target enrollment in ENLIGHTED as of the November 5, 2024 data cutoff.

About ImPact Biotech

ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: www.impactbiotech.com and the ENLIGHTED clinical trial website (for the US): https://www.enlighted-study.com.

Contacts

Global Head of Business Development
Guy Schmidt
guy.schmidt@impactbiotech.com

Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference




Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference

CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting at the 37th Annual Piper Sandler Healthcare conference on Wednesday, December 3rd at 9:00-9:25 am ET in New York, NY. During the conference, Carlsmed Management will be hosting 1×1 investor meetings.

A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://investors.carlsmed.com/.

About Carlsmed, Inc.

Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Investor Relations
Caroline Corner, PhD
IR@Carlsmed.com

Media
LeAnn Burton
Senior Director Brand Marketing
LBurton@Carlsmed.com

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)




BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on November 17, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com   
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

Patriot Mobile Named SoldierStrong’s 2025 Corporate Recipient of the Annual Commitment to Service Award




Patriot Mobile Named SoldierStrong’s 2025 Corporate Recipient of the Annual Commitment to Service Award

STAMFORD, Conn., Nov. 19, 2025 (GLOBE NEWSWIRE) — SoldierStrong, the national nonprofit committed to delivering revolutionary medical technologies to America’s veterans, is proud to announce Patriot Mobile as the 2025 Corporate Recipient of its Annual Commitment to Service Award.

The Commitment to Service Award recognizes companies and individuals who have demonstrated exemplary and inspirational leadership, and provided material support to SoldierStrong’s mission. Recipients leverage their talents and resources to help elevate the standard of excellence in health care available to our nation’s veterans.

Since 2013, Patriot Mobile has offered Americans a reliable alternative for cell phone service, delivering nationwide 4G and 5G coverage along with exceptional U.S.-based customer support. Patriot Mobile has long been a strong advocate for military, veterans, first responders, and their families by giving a portion of every dollar to support organizations that fight for our freedom.

“At Patriot Mobile, we believe that business should be a force for good, and Soldier Strong is an example how much good can be done when we unite purpose with passion,” said Glenn Story, Patriot Mobile’s Founder and CEO. “We are so passionate about taking care of our military, veterans and first responders, we made it one of our main pillars of giving. I accept this award as a call to continue serving our heroes with the same dedication they’ve shown serving America.”

SoldierStrong has been honored to join forces with Patriot Mobile over the past year in a shared dedication to supporting veterans and their families. Contributions from Patriot Mobile have helped support SoldierStrong’s efforts to donate wearable robotic exoskeletons, known as SoldierSuits, which are used to aid paralyzed veterans in walking again, as well as BraveMind virtual reality software and hardware systems used to treat post-traumatic stress in post-9/11 veterans. SoldierStrong has donated more than $7.3 million in revolutionary medical technologies since 2013, including 30 SoldierSuits and 31 BraveMind systems to date.

“SoldierStrong is proud to recognize Patriot Mobile for their steadfast commitment to our veterans and our mission, which has not only transformed the lives of countless individuals but has also set a shining example for all Americans to follow,” said Dr. Chris Meek, co-founder and chairman of SoldierStrong. “Through Patriot Mobile’s leadership, the company has uplifted veterans and ignited a flame of hope and resilience that inspires us all to strive for greater heights in our mission to support those who have sacrificed so much for our nation.”

Past corporate and individual recipients include WWE Inc., United Rentals Inc., S&P Global, Bobby Rahal Automotive Group, Flags of Valor, Martha MacCallum of FOX News, IndyCar driver Graham Rahal, former Congressman Jon Runyan, and Lieutenant General (Ret.) Patricia D. Horoho, the 43rd Surgeon General of the U.S. Army.

Patriot Mobile CEO Glenn Story accepted the award last night at an event hosted by the company to benefit SoldierStrong at the American Journey Experience in Irving, Texas.

About SoldierStrong

Since 2009, SoldierStrong has assisted America’s military veterans in taking their next steps forward in life after service. Our mission is fully realized through the donation of revolutionary medical technology to Veterans Affairs medical facilities and individual veterans across the country. These revolutionary medical technologies include the SoldierSuit, a wearable robotic exoskeleton used to help paralyzed and injured veterans walk again, and the BraveMind virtual reality system used to treat post-9/11 veterans living with the devastating impacts of post-traumatic stress (PTS). To date, SoldierStrong has donated more than $7.3 million in advanced medical technology, including 30 SoldierSuits and 31 BraveMind systems. For more information, visit soldierstrong.org.

About Patriot Mobile

Patriot Mobile is America’s ONLY Christian conservative wireless provider. Since 2013, Patriot Mobile has given Americans a conservative alternative for their cell service by providing dependable nationwide coverage on 4G and 5G networks and exceptional U.S.-based customer support. Patriot Mobile gives a portion of every dollar to support organizations that fight for our freedom. Patriot Mobile’s mission is to passionately defend our God-given rights and freedoms, and to glorify God always. For more information, visit www.patriotmobile.com.

Contact: Christina Stroback (SoldierStrong)
319.936.9300
christina@soldierstrong.org
Contact: Leigh Wambsganss (Patriot Mobile)
media@patriotmobile.com

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”




Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Company has pro forma cash of approximately $14 million following recent public offering

HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under the stock ticker “SLRX.”

S&P CapIQ inaccurately characterized the Salarius Pharmaceuticals and Decoy Therapeutics merger and inaccurately stated that the Company had been delisted from the Nasdaq Capital Market. The Company is working to have this inaccurate information corrected. Similar inaccuracies that appeared on Yahoo Finance were corrected earlier this week.

On November 13, 2025, Salarius completed an underwritten public offering raising gross proceeds of $8 million and consummated the previously announced merger with Decoy Therapeutics (Decoy). As of the date of this release, the combined company had pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. The company is focused on advancing Decoy’s pipeline of peptide conjugate therapeutics engineered through its IMP³ACT platform that reduces the complexity of drug development and manufacturing.

During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress on other programs including a novel broad-acting antiviral to treat flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers.

About Salarius Pharmaceuticals
Salarius is focused on advancing Decoy’s pipeline of peptide conjugate therapeutics through its IMP³ACT platform, which uses artificial intelligence (AI), machine learning (ML) and high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the combined company, including without limitation, statements relating to plans and expectations relating to the business, scientific advisory board, products, including expected achievement of milestones for its lead asset and future prospects of the combined company. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of the combined company, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: risks related to the combined company’s ability to satisfy the initial listing standards in the required timeframe; risks that the combined company will not achieve the synergies expected from the proposed merger; risks that the combined company will not obtain sufficient financing to execute on their business plans; risks that Salarius will be unable to obtain stockholder approval for the conversion of the preferred stock; and risks related to the combined company’s products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by Salarius in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Salarius’ actual results may vary materially from those expected or projected.

CONTACT:

Alliance Advisors IR
Jody Cain
jcain@allianceadvisors.com
310-691-7100

IPSEN – Buy-back programme – Art 5 of MAR – Week 46 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 46 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 46_2025

IPSEN – Buy-back programme – Art 5 of MAR – Week 46 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 46 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 46_2025